Goldman Sachs
BBIO icon

Goldman Sachs’s BridgeBio Pharma BBIO Stock Holding History

Goldman Sachs’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.46M Buy
60,000
+10,000
+20% +$725K ﹤0.01% 3819
2025
Q4 		$3.82M Buy
+50,000
New +$3.28M ﹤0.01% 3987
2025
Q3 		– Sell
-45,000
Closed -$1.94M – 6337
2025
Q2 		$1.94M Sell
45,000
-20,000
-31% -$727K ﹤0.01% 4205
2025
Q1 		$2.25M Buy
+65,000
New +$2.19M ﹤0.01% 4059

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's BBIO Position: Q1 2026 in Review

Goldman Sachs increased its BridgeBio Pharma (BBIO) stake by 6.4% in Q1 2026, buying an estimated $8.33M and bringing the position to 1,897,716 shares worth $141M. The position accounts for 0.02% of the portfolio, ranked #850.

Goldman Sachs first reported a position in BBIO in Q2 2019 and has held it in 28 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Goldman Sachs held 1,897,716 shares of BridgeBio Pharma worth $141M as of Q1 2026.
  • Goldman Sachs bought 114,883 BridgeBio Pharma shares in Q1 2026, an estimated $8.33M.
  • BridgeBio Pharma made up 0.02% of Goldman Sachs's portfolio in Q1 2026, its #850 holding.
  • Goldman Sachs first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 28 quarters since.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.